Disparities Exist in Delivering Innovative Cancer Therapies
How can disparities be mitigated when it comes to giving patients the newest and most innovative cancer treatments?
Delivering new and innovative cancer therapies, such as CAR T-cell therapy, come with disparities, explained John Sweetenham, MD, FACP, FRCP, director of clinical affairs and physician in chief at Huntsman Cancer Institute, University of Utah, in Salt Lake City.
These disparities go beyond those that first come to mind, such as race and ethnicity. Patients face barriers in entering clinical trials and receiving the latest standard of care if they live in rural areas.
Three aspects could help fix this problem, said Sweetenham: more education about new advances; more robust funding systems; and a more sophisticated technological platform for clinicians to communicate with patients.
FDA Grants Pirtobrutinib Accelerated Approval to Treat CLL/SLL in the Third Line
December 2nd 2023The FDA has approved the non-covalent BTK inhibitor, pirtobrutinib, to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already undergone 2 lines of therapy.
